1 week ago
1
Zydus Lifesciences Ltd has announced that Zydus Worldwide DMCC, it’s subsidiary of has signed a definitive agreement, through its wholly owned acquisition subsidiary Zara Merger Sub Inc., with Assertio Holdings, Inc. a U.S.-based pharmaceutical institution focused connected specialty and oncology supportive-care therapies to get each outstanding shares of Assertio for $23.50 per stock successful cash, representing full information of $ 166.4 cardinal connected a fully-diluted basis.
“The acquisition provides Zydus with an established U.S. specialty oncology commercialized platform, anchored by Assertio’s beingness successful oncology supportive care,” Zydus said.
Assertion’s portfolio includes ROLVEDON® (eflapegrastimxnst), approved as a BLA by USFDA for agelong acting GCSF biologic for the prevention of febrile neutropenia successful big crab patients receiving myelosuppressive chemotherapy.
Under the presumption of the merger agreement, Zydus volition commence a tender connection to get each outstanding shares of Assertio communal stock.
The transaction is structured arsenic a tender connection to beryllium followed by a merger, taxable to customary closing conditions, including the tender of shares representing astatine least a bulk of the full fig of outstanding shares of Assertio communal stock.
Following the palmy completion of the tender offer, Zydus volition get each remaining shares not tendered successful the tender connection done a second-step merger astatine the aforesaid terms paid successful the tender offer.
The tender connection is expected to commence wrong 5 concern days pursuing the day of the merger agreement. The transaction is expected to adjacent in the fiscal twelvemonth 2026-27, subject to restitution of each closing conditions.
Sharvil P. Patel, Managing Director, Zydus Lifesciences Ltd, said, “This transaction represents a strategical measurement successful strengthening our specialty and oncology footprint successful the U.S. Assertio brings a focused commercialized level and an approved oncology plus that aligns good with our semipermanent strategy of gathering differentiated, durable specialty businesses globally.”
